RT Journal Article
T1 Endostatin genetically engineered placental mesenchymal stromal cells carrying mesoporous silica nanoparticles for combined chemo- and antiangiogenic therapy
A1 De la Torre, Paz
A1 Paris, J. L.
A1 Fernández de la Torre, Miguel
A1 Vallet Regí, María Dulce Nombre
A1 Flores, Ana I.
AB Combination therapies constitute a powerful tool for cancer treatment. By combining drugs with different mechanisms of action, the limitations of each individual agent can be overcome, while increasing therapeutic benefit. Here, we propose employing tumor-migrating decidua-derived mesenchymal stromal cells as therapeutic agents combining antiangiogenic therapy and chemotherapy. First, a plasmid encoding the antiangiogenic protein endostatin was transfected into these cells by nucleofection, confirming its expression by ELISA and its biological effect in an ex ovo chick embryo model. Second, doxorubicin-loaded mesoporous silica nanoparticles were introduced into the cells, which would act as vehicles for the drug being released. The effect of the drug was evaluated in a coculture in vitro model with mammary cancer cells. Third, the combination of endostatin transfection and doxorubicin-nanoparticle loading was carried out with the decidua mesenchymal stromal cells. This final cell platform was shown to retain its tumor-migration capacity in vitro, and the combined in vitro therapeutic efficacy was confirmed through a 3D spheroid coculture model using both cancer and endothelial cells. The results presented here show great potential for the development of combination therapies based on genetically-engineered cells that can simultaneously act as cellular vehicles for drug-loaded nanoparticles.
PB MDPI
SN 1999-4923
YR 2021
FD 2021-02-10
LK https://hdl.handle.net/20.500.14352/7795
UL https://hdl.handle.net/20.500.14352/7795
LA eng
NO RESEARCHER ID D-9318-2017  (Juan Luis Paris de la Fuente)ORCID 0000-0001-8950-283X (Juan Luis Paris de la Fuente)RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)
NO Unión Europea. Horizonte 2020
NO Instituto de Salud Carlos III/FEDER/MINECO
NO Fundacion Francisco Soria Melguizo
DS Docta Complutense
RD 8 abr 2025